Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02313623 · ClinicalTrials.gov registry record
MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 600
- Enrollment target
NCT02313623: Completed study, sponsored by Yale University.
NCT02313623 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02313623 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
Study Summary
The investigators hypothesize that this single-cell analysis can be used to evaluate prostate needle-core biopsies prospectively even in non-homogenous samples by providing profiles of proteomic and phenotypic signatures. These profiles will in turn enable better predictions of the malignant progression of prostate cancers in the settings of current clinical practice.
Primary Outcome
how often are primary prostate cancer cells able to be grown in culture
Interventions
- PROCEDURE Prostate Fusion Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2013-07 |
| Est. Completion | 2025-10-01 |
What the finished NCT02313623 record still lists
NCT02313623 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Prostate Fusion Biopsy is the first listed.
NCT02313623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02313623 about?
NCT02313623 is a clinical study titled "MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research". The investigators hypothesize that this single-cell analysis can be used to evaluate prostate needle-core biopsies prospectively even in non-homogenous samples by providing profiles of proteomic and phenotypic signatures. These profiles will in turn enable better predictions of the malignant progres...
What is the current status of trial NCT02313623?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2013-07. Estimated completion is 2025-10-01.
What interventions are being tested in trial NCT02313623?
The interventions under investigation include: Prostate Fusion Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02313623?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia